Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14283980 | 0.78 | MEN1 (0.35) | MEN1KMT2ALMNAKDM4EALDH1A1 | |
| SCHEMBL1047906 | 0.78 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL6183305 | 0.74 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL3283992 | 0.71 | BCL2L1 (0.38) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL10533578 | 0.68 | KDM4E (0.33) | KDM4EMAPK1 | |
| SCHEMBL1048153 | 0.65 | MEN1 (0.51) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL24592550 | 0.65 | KDM4E (0.32) | KDM4EMAPK1 | |
| SCHEMBL12909512 | 0.63 | ALDH1A1 (0.37) | MEN1KMT2ALMNAUSP2KDM4E | |
| SCHEMBL14283979 | 0.63 | KDM4E (0.40) | MEN1KMT2ALMNAUSP2KDM4E | |
| SCHEMBL992964 | 0.62 | SENP1 (0.39) | SENP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1820790-B1 | 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them | INVISTA TECH SARL (CH) | 2011-05-11 | — | — | EP | disclosed |
| EP-2279994-A1 | 3-Alkylated-5,5',6,6',7,7',8,8'-Octahydro-2,2'-Binaphthols and 3,3'-Dialkylated-5,5',6,6',7,7',8,8'-Octahydro-2,2'-Binaphthols and processes for making them | Invista Technologies S.à.r.l. (CH) | 2011-02-02 | — | — | EP | disclosed |
| EP-2275397-A1 | 3-alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them | Invista Technologies S.à.r.l. (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-1465851-B1 | 3-ALKYLATED-5,5',6,6',7,7',8,8'-OCTAHYDRO-2,2'-BINAPHTHOLS AND 3,3'-DIALKYLATED-5,5',6,6',7,7',8,8'-OCTAHYDRO-2,2'-BINAPHTHOLS AND PROCESSES FOR MAKING THEM | INVISTA TECH SARL (CH) | 2010-06-23 | — | — | EP | disclosed |
| EP-1820790-A2 | 3-Alkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and process for making them | E.I.Du pont de nemours and company (US) | 2007-08-22 | — | — | EP | disclosed |
| US-7071365-B2 | 3-alkylated-5,5′,6,6′, 7, 7′, 8, 8′—octahydro-2, 2′-binaphthols and 3, 3′-dialkylated- 5, 5′, 6, 6′, 7, 7′, 8, 8′-octahydro—2, 2′-binaphthols and processes for making | INVISTA NORTH AMERICA S.A.R.L. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050182279-A1 | 3 - Alkylated-5, 5',6, 6', 7, 7', 8, 8' - octahydro-2, 2' - binaphthols and 3, 3' - dialkylated- 5, 5', 6, 6', 7, 7', 8, 8' - octahydro - 2, 2' - binaphthols and processes for making | INVISTA NORTH AMERICA S.A.R.L. | 2005-08-18 | — | — | US | disclosed |
| US-20030100803-A1 | 3-Alkylated-5,5',6,6',7,7,'8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them | E.I. DU PONT DE NEMOURS AND COMPANY | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100803-A1 | 3-Alkylated-5,5',6,6',7,7,'8,8'-octahydro-2,2'-binaphthols and 3,3'-dialkylated-5,5',6,6',7,7',8,8'-octahydro-2,2'-binaphthols and processes for making them | ALKBH3, ALKBH2, UGT8 | MEN1 3089/4885KMT2A 1914/4885LMNA 3075/4885 |
| US-20050182279-A1 | 3 - Alkylated-5, 5',6, 6', 7, 7', 8, 8' - octahydro-2, 2' - binaphthols and 3, 3' - dialkylated- 5, 5', 6, 6', 7, 7', 8, 8' - octahydro - 2, 2' - binaphthols and processes for making | ALKBH3, UGT8, ALKBH2 | MEN1 2936/4885KMT2A 1953/4885LMNA 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.